89 related articles for article (PubMed ID: 9215602)
1. Fostriecin: a review of the preclinical data.
de Jong RS; de Vries EG; Mulder NH
Anticancer Drugs; 1997 Jun; 8(5):413-8. PubMed ID: 9215602
[TBL] [Abstract][Full Text] [Related]
2. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
3. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
[TBL] [Abstract][Full Text] [Related]
4. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
6. Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.
Takeuchi T; Takahashi N; Ishi K; Kusayanagi T; Kuramochi K; Sugawara F
Bioorg Med Chem; 2009 Dec; 17(23):8113-22. PubMed ID: 19857968
[TBL] [Abstract][Full Text] [Related]
7. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Francis GE; Tejedor MC; Berney JJ; Chresta CM; Delgado C; Patel P
Leukemia; 1994 Jan; 8(1):121-8. PubMed ID: 8289477
[TBL] [Abstract][Full Text] [Related]
8. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of type II topoisomerase by fostriecin.
Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
[TBL] [Abstract][Full Text] [Related]
10. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization.
Ho DT; Roberge M
Carcinogenesis; 1996 May; 17(5):967-72. PubMed ID: 8640945
[TBL] [Abstract][Full Text] [Related]
11. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
Walsh AH; Cheng A; Honkanen RE
FEBS Lett; 1997 Oct; 416(3):230-4. PubMed ID: 9373158
[TBL] [Abstract][Full Text] [Related]
12. Response of murine small intestine to combined treatment with fostriecin and X rays.
Rao KR; Fritz-Niggli H
Br J Radiol; 1990 Apr; 63(748):286-9. PubMed ID: 2346866
[TBL] [Abstract][Full Text] [Related]
13. Total synthesis of an antitumor antibiotic, Fostriecin (CI-920).
Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
J Am Chem Soc; 2003 Jul; 125(27):8238-43. PubMed ID: 12837094
[TBL] [Abstract][Full Text] [Related]
14. Fostriecin: chemistry and biology.
Lewy DS; Gauss CM; Soenen DR; Boger DL
Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
[TBL] [Abstract][Full Text] [Related]
15. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
[TBL] [Abstract][Full Text] [Related]
16. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats.
Susick RL; Hawkins KL; Pegg DG
Fundam Appl Toxicol; 1990 Aug; 15(2):258-69. PubMed ID: 2227154
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
18. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.
Pillon L; Moore MJ; Thiessen JJ
Ther Drug Monit; 1994 Apr; 16(2):186-90. PubMed ID: 8009568
[TBL] [Abstract][Full Text] [Related]
19. Total synthesis of fostriecin (CI-920).
Boger DL; Ichikawa S; Zhong W
J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
[TBL] [Abstract][Full Text] [Related]
20. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts.
Frosina G; Rossi O
Carcinogenesis; 1992 Aug; 13(8):1371-7. PubMed ID: 1323426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
